<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001250'>Seizures</z:hpo> are a frequent complication associated with several neurogenetic disorders </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="35623">Antiepileptic</z:chebi> medications remain the mainstay of treatment in these patients </plain></SENT>
<SENT sid="2" pm="."><plain>We summarized the available data associated with various <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> therapies used to treat patients with neurogenetic disorders who experienced recurrent <z:hpo ids='HP_0001250'>seizures</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>A MEDLINE search was conducted to identify articles and abstracts describing the use of <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> therapy for the treatment of various neurogenetic syndromes </plain></SENT>
<SENT sid="4" pm="."><plain>Of <z:hpo ids='HP_0000001'>all</z:hpo> the neurogenetic syndromes, only <z:hpo ids='HP_0000729'>autism spectrum disorders</z:hpo>, <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e>, <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e>, Dravet syndrome, and tuberous <z:mp ids='MP_0000612'>sclerosis</z:mp> complex were identified as having sufficient published information to evaluate therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Some efficacy trends were identified, including frequent successes with <z:chebi fb="0" ids="39867">valproic acid</z:chebi> with clonazepam for <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> with <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e>; <z:chebi fb="0" ids="39867">valproic acid</z:chebi>, stiripentol, and clobazam (triple combination therapy) for <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> with Dravet syndrome; and vigabatrin for <z:e sem="disease" ids="C0037769" disease_type="Disease or Syndrome" abbrv="">infantile spasms</z:e> associated with tuberous <z:mp ids='MP_0000612'>sclerosis</z:mp> complex </plain></SENT>
<SENT sid="6" pm="."><plain>Due to a paucity of information regarding the mechanisms by which <z:hpo ids='HP_0001250'>seizures</z:hpo> are generated in the various disorders, approach to <z:hpo ids='HP_0001250'>seizure</z:hpo> control is primarily based on clinical experience and a limited amount of study data exploring patient outcomes </plain></SENT>
<SENT sid="7" pm="."><plain>Although exposure of the developing brain to <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> medications is of some concern, the control of <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epileptic</z:e> activity is an important undertaking in these individuals, as the severity of eventual <z:hpo ids='HP_0001263'>developmental delay</z:hpo> often appears to correlate with the severity of <z:hpo ids='HP_0001250'>seizures</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>As such, early aggressive therapy is warranted </plain></SENT>
</text></document>